{"id":61116,"date":"2024-02-28T07:25:37","date_gmt":"2024-02-28T07:25:37","guid":{"rendered":"https:\/\/medsname.com\/champix\/"},"modified":"2026-05-01T10:49:16","modified_gmt":"2026-05-01T10:49:16","slug":"champix","status":"publish","type":"product","link":"https:\/\/medsbase.com\/cs\/product\/champix\/","title":{"rendered":"Champix"},"content":{"rendered":"

<\/p>\n

\n

⚡ Quick Answer — Champix — varenicline 1 mg for smoking cessation<\/h3>\n

Champix is varenicline 1 mg, an α4β2 nicotinic-acetylcholine partial agonist that reduces nicotine cravings and the rewarding effect of smoking. Set a quit date 8–14 days into a 12-week course; titrate from 0.5 mg once daily up to 1 mg twice daily. Most effective when combined with behavioural support; the 2016 EAGLES trial removed the historical neuropsychiatric black-box.<\/p>\n<\/div>\n

\nCo z\u00edsk\u00e1te s MedsBase:<\/strong> V\u00fdrobce certifikovan\u00fd WHO-GMP \u00b7 Diskr\u00e9tn\u00ed balen\u00ed \u00b7 Celosv\u011btov\u00e1 doprava \u00b7 V\u00edce ne\u017e 1 400 ov\u011b\u0159en\u00fdch recenz\u00ed z\u00e1kazn\u00edk\u016f<\/a>\n<\/div>\n

\ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n

Pro\u010d objedn\u00e1vat z MedsBase<\/h3>\n

Na\u0161e generick\u00e9 l\u00e9ky poch\u00e1zej\u00ed od v\u00fdrobc\u016f certifikovan\u00fdch WHO-GMP a jsou expedov\u00e1ny po cel\u00e9m sv\u011bt\u011b v diskr\u00e9tn\u00edm, nen\u00e1padn\u00e9m balen\u00ed \u2013 na vn\u011bj\u0161\u00ed stran\u011b bal\u00edku nen\u00ed uveden n\u00e1zev l\u00e9ku. Platby kartou jsou sm\u011brov\u00e1ny prost\u0159ednictv\u00edm regulovan\u00e9ho procesoru (popisky na v\u00fdpisu zahrnuj\u00ed regulovan\u00e9ho procesora plateb kartou \u2013 nikdy \u201cMedsBase\u201d nebo n\u00e1zev l\u00e9ku). P\u0159ij\u00edm\u00e1me tak\u00e9 kryptom\u011bny a bankovn\u00ed p\u0159evody SEPA. Ka\u017ed\u00e1 objedn\u00e1vka je zaji\u0161t\u011bna na\u0161\u00ed politikou p\u0159eposl\u00e1n\u00ed.<\/p>\n

What is Champix?<\/h2>\n

Champix is a smoking-cessation aid containing varenicline 1 mg<\/strong> (film-coated tablets), supplied by Pfizer. It is a selective partial agonist at the α4β2 subtype of the neuronal nicotinic acetylcholine receptor — the same receptor nicotine binds — and is one of the most effective monotherapies for tobacco dependence, with cessation rates roughly two to three times those of placebo and consistently superior to single-agent nicotine-replacement therapy in head-to-head trials.<\/p>\n

How varenicline works<\/h2>\n

Varenicline binds the α4β2 nicotinic receptor with both agonist and antagonist<\/strong> properties: as a partial agonist it produces about 30–60% of nicotine’s dopamine release, dampening cravings and withdrawal; as an antagonist it occupies the receptor and blocks the dopaminergic surge from any cigarette smoked while on therapy, so a cigarette during the course feels much less rewarding than usual. This dual action distinguishes it from bupropion (an atypical antidepressant with weak nicotinic antagonism) and from nicotine-replacement therapy (full agonism only).<\/p>\n

How Champix is used<\/h2>\n

The standard adult course is 12 t\u00fddnech<\/strong>. Set a quit date 8–14 days into the course — do not stop smoking on day 1. An alternative “flexible quit” approach lets the smoker reduce gradually over the first 12 weeks and quit any time before the end.<\/p>\n\n\n\n\n\n\n\n\n
Days<\/th>\nD\u00e1vka<\/th>\nPozn\u00e1mky<\/th>\n<\/tr>\n<\/thead>\n
Days 1–3<\/td>\n0.5 mg once daily<\/td>\nAfter breakfast<\/td>\n<\/tr>\n
Days 4–7<\/td>\n0.5 mg twice daily<\/td>\n12 hours apart<\/td>\n<\/tr>\n
Day 8 onwards (week 2–12)<\/td>\n1 mg twice daily<\/strong><\/td>\nMaintenance; quit date in this window<\/td>\n<\/tr>\n
Optional 12-week extension<\/td>\n1 mg twice daily<\/td>\nFor those who quit successfully — doubles 1-year abstinence rates<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Take with a full glass of water after a meal<\/strong> — nausea is the most common reason for discontinuation and is reduced by food and adequate hydration. If 1 mg twice daily is not tolerated, dropping back to 0.5 mg twice daily is acceptable and still active.<\/p>\n

\u00daprava d\u00e1vky p\u0159i ren\u00e1ln\u00ed insuficienci<\/h2>\n

Varenicline is excreted ~92% unchanged in urine. Dose adjustment is required in significant renal impairment:<\/p>\n\n\n\n\n\n\n\n
eGFR (mL\/min\/1,73 m\u00b2)<\/th>\nMaxim\u00e1ln\u00ed d\u00e1vka<\/th>\n<\/tr>\n<\/thead>\n
≥ 30 (mild–moderate impairment)<\/td>\nStandard 1 mg BID<\/td>\n<\/tr>\n
< 30 (severe impairment)<\/td>\n1 mg once daily (titrate from 0.5 mg daily)<\/td>\n<\/tr>\n
Hemodial\u00fdza<\/td>\n0.5 mg once daily, may titrate to 1 mg once daily<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
Neuropsychiatric history.<\/strong> The original FDA black-box warning (2009) was removed in 2016<\/strong> after the EAGLES trial (8,144 randomised smokers, including a stable-psychiatric cohort) found no statistically significant excess of clinically significant neuropsychiatric events versus placebo, NRT, or bupropion. However, smoking cessation itself can unmask underlying mood symptoms; patients with serious mental illness should still be monitored for new or worsening depression, anxiety, agitation, or suicidal ideation, especially in the first 4 weeks. Stop and contact a clinician if these emerge.<\/div>\n

\u010cast\u00e9 ne\u017e\u00e1douc\u00ed \u00fa\u010dinky<\/h2>\n